Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer C. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010; 295:100-9.
30.03.2010
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
30.03.2010
Cancer Lett 2010; 295:100-9
Zitzmann Kathrin, Rüden Janina von, Brand Stephan, Göke Burkhard, Lichtl Jennifer, Spöttl Gerald, Auernhammer Christoph J
Weiter
